Ozempic Goes Generic —But Not in the US

A drug that helped turn Novo Nordisk into Europe's most valuable company is about to lose its monopoly grip across much of the globe. Patent protections on semaglutide—sold as Ozempic for diabetes and Wegovy for weight loss—expire Saturday in several of the world's most populous countries, opening the...